Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883581413> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2883581413 abstract "Suloctidil(S.) - 1-(4-isopropylthiophenyl)-2n octylamino- propanol - is a vaso-active compound endowed with antiplatelet and antithrombotic properties. After administration to healthy volunteers it was found to inhibit thrombofax and collagen induced aggregation. In a double blind cross-over set up-S. 200 mg T.I.D. vs. placebo - the induction of circulating platelet aggregates by venous occlusion was highly significantly inhibited. Following positive results on P.S.T. in the baboon a.-v. shunt model, studies on P.S.T. were initiated in man: 23 patients with valvular prosthesis, all under coumarine therapy, were admitted to a double blind parallel study of 6 weeks duration cqnparing S. 200 mg T.I.D. (n=ll) to placebo (n=12). P.S.T. (51Cr-labeling) measured before and during the last week of the study, was unchanged in the placebo and significantly increased in the S. treated group. Similar results were obtained measuring platelet regeneration time according to a modified Stewart method in an open study (n=6) in valvular prosthesis and in a double blind parallel study (S. n=25; placebo n=27) in valvular prosthesis, coronary artery disease and myocardial infarction. In patients with obstructive arteriopathy (Fontaine II & III) inhibition of thrombine induced platelet M.D.A. production and reduction of increased βTG levels have been observed under S. therapy at rest and after ischemia. In 31 patients suffering from recurr. ven. thrombosis, admitted to a double blind cross-over study comparing S. 200 mg T.I.D. to placebo-2 periods of 3 months each - a striking difference in the clinical evolution (placebo 12 events, S. none) was paralleled by consistent changes in biological parameters such as platelet aggregation, PF4 and βTG. The results obtained in pharmacological as well as in efficacy studies have justified the initiation of larger scale trials to evaluate the compounds antithrombotic potential." @default.
- W2883581413 created "2018-08-03" @default.
- W2883581413 creator A5060300736 @default.
- W2883581413 creator A5085302307 @default.
- W2883581413 date "1981-01-01" @default.
- W2883581413 modified "2023-09-23" @default.
- W2883581413 title "Suloctidil: Review Of Its Antiplatelet And Antithrombotic Properties In Man" @default.
- W2883581413 doi "https://doi.org/10.1055/s-0038-1652912" @default.
- W2883581413 hasPublicationYear "1981" @default.
- W2883581413 type Work @default.
- W2883581413 sameAs 2883581413 @default.
- W2883581413 citedByCount "0" @default.
- W2883581413 crossrefType "proceedings-article" @default.
- W2883581413 hasAuthorship W2883581413A5060300736 @default.
- W2883581413 hasAuthorship W2883581413A5085302307 @default.
- W2883581413 hasBestOaLocation W28835814131 @default.
- W2883581413 hasConcept C126322002 @default.
- W2883581413 hasConcept C141071460 @default.
- W2883581413 hasConcept C142724271 @default.
- W2883581413 hasConcept C164705383 @default.
- W2883581413 hasConcept C204787440 @default.
- W2883581413 hasConcept C27081682 @default.
- W2883581413 hasConcept C2777015399 @default.
- W2883581413 hasConcept C2778213512 @default.
- W2883581413 hasConcept C2778715743 @default.
- W2883581413 hasConcept C2991744798 @default.
- W2883581413 hasConcept C42219234 @default.
- W2883581413 hasConcept C500558357 @default.
- W2883581413 hasConcept C71924100 @default.
- W2883581413 hasConcept C89560881 @default.
- W2883581413 hasConceptScore W2883581413C126322002 @default.
- W2883581413 hasConceptScore W2883581413C141071460 @default.
- W2883581413 hasConceptScore W2883581413C142724271 @default.
- W2883581413 hasConceptScore W2883581413C164705383 @default.
- W2883581413 hasConceptScore W2883581413C204787440 @default.
- W2883581413 hasConceptScore W2883581413C27081682 @default.
- W2883581413 hasConceptScore W2883581413C2777015399 @default.
- W2883581413 hasConceptScore W2883581413C2778213512 @default.
- W2883581413 hasConceptScore W2883581413C2778715743 @default.
- W2883581413 hasConceptScore W2883581413C2991744798 @default.
- W2883581413 hasConceptScore W2883581413C42219234 @default.
- W2883581413 hasConceptScore W2883581413C500558357 @default.
- W2883581413 hasConceptScore W2883581413C71924100 @default.
- W2883581413 hasConceptScore W2883581413C89560881 @default.
- W2883581413 hasLocation W28835814131 @default.
- W2883581413 hasOpenAccess W2883581413 @default.
- W2883581413 hasPrimaryLocation W28835814131 @default.
- W2883581413 hasRelatedWork W2002227424 @default.
- W2883581413 hasRelatedWork W2049397185 @default.
- W2883581413 hasRelatedWork W2085050035 @default.
- W2883581413 hasRelatedWork W2399063111 @default.
- W2883581413 hasRelatedWork W2417414779 @default.
- W2883581413 hasRelatedWork W2470867510 @default.
- W2883581413 hasRelatedWork W2517015656 @default.
- W2883581413 hasRelatedWork W2790353319 @default.
- W2883581413 hasRelatedWork W3094206399 @default.
- W2883581413 hasRelatedWork W3130040365 @default.
- W2883581413 isParatext "false" @default.
- W2883581413 isRetracted "false" @default.
- W2883581413 magId "2883581413" @default.
- W2883581413 workType "article" @default.